SG11201906973TA - Multiple transgene recombinant adenovirus - Google Patents

Multiple transgene recombinant adenovirus

Info

Publication number
SG11201906973TA
SG11201906973TA SG11201906973TA SG11201906973TA SG11201906973TA SG 11201906973T A SG11201906973T A SG 11201906973TA SG 11201906973T A SG11201906973T A SG 11201906973TA SG 11201906973T A SG11201906973T A SG 11201906973TA SG 11201906973T A SG11201906973T A SG 11201906973TA
Authority
SG
Singapore
Prior art keywords
international
pct
san diego
recombinant adenovirus
english
Prior art date
Application number
SG11201906973TA
Inventor
Tony R Reid
Bryan T Oronsky
Christopher Larson
Original Assignee
Epicentrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epicentrx Inc filed Critical Epicentrx Inc
Publication of SG11201906973TA publication Critical patent/SG11201906973TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 02 August 2018 (02.08.2018) WIPO I PCT (51) International Patent Classification: Cl 2N 7/01 (2006.01) A61K 35/761 (2015.01) Cl 2N 15/861 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2018/016032 (22) International Filing Date: 30 January 2018 (30.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/452,342 30 January 2017 (30.01.2017) US 62/520,945 16 June 2017 (16.06.2017) US (71) Applicant: EPICENTRX, INC. [US/US]; 4445 Eastgate Mall, Suite 200, San Diego, CA 92121 (US). (72) Inventors: REID, Tony R.; 5517 Carriage Court, San Diego, CA 92130 (US). ORONSKY, Bryan T.; 28540 Matadero Creek Lane, Los Altos Hills, CA 94022 (US). LARSON, Christopher; 3815 Lebon Dr. Apt. 335, San Diego, CA 92122 (US). (74) Agent: DAVENPORT, Andrew M. et al.; Goodwin Proc- ter LLP, 100 Northern Avenue, Boston, MA 02210 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) 1-1 O \" (57) : The invention provides a recombinant adenovirus comprising two (or more) therapeutic transgenes, e.g., CD80 and 0 CD137L. The transgenes are preferably inserted into an Elb-19K insertion site and/or an E3 insertion site. omit VIII °nolo 010 Holimo Ill ono mil (10) International Publication Number WO 2018/140973 Al (54) Title: MULTIPLE TRANSGENE RECOMBINANT ADENOVIRUS
SG11201906973TA 2017-01-30 2018-01-30 Multiple transgene recombinant adenovirus SG11201906973TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762452342P 2017-01-30 2017-01-30
US201762520945P 2017-06-16 2017-06-16
PCT/US2018/016032 WO2018140973A1 (en) 2017-01-30 2018-01-30 Multiple transgene recombinant adenovirus

Publications (1)

Publication Number Publication Date
SG11201906973TA true SG11201906973TA (en) 2019-08-27

Family

ID=62978741

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906973TA SG11201906973TA (en) 2017-01-30 2018-01-30 Multiple transgene recombinant adenovirus

Country Status (12)

Country Link
US (1) US20190352616A1 (en)
EP (1) EP3574090A4 (en)
JP (1) JP2020505049A (en)
KR (1) KR20190128634A (en)
CN (1) CN110741080A (en)
AU (1) AU2018213417A1 (en)
BR (1) BR112019015600A2 (en)
CA (1) CA3052090A1 (en)
IL (1) IL268291A (en)
MX (1) MX2019008921A (en)
SG (1) SG11201906973TA (en)
WO (1) WO2018140973A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014236207B2 (en) 2013-03-14 2019-05-23 Salk Institute For Biological Studies Oncolytic adenovirus compositions
JP7054527B2 (en) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ High-throughput assay to measure adenovirus replication kinetics
KR20220163505A (en) 2016-02-23 2022-12-09 솔크 인스티튜트 포 바이올로지칼 스터디즈 Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
US20200155625A1 (en) * 2017-05-24 2020-05-21 Epicentrx, Inc. Anti-angiogenic adenovirus
WO2022007800A1 (en) * 2020-07-06 2022-01-13 嘉兴安宇生物科技有限公司 Recombinant adenovirus vaccine for african swine fever and method for constructing same
EP4349975A1 (en) * 2021-05-25 2024-04-10 Voncolytic Therapeutics Co., Ltd. Chimeric broad-spectrum oncolytic adenovirus with multiple mechanisms synergizing with and enhancing efficacy of immunotherapy, and application thereof in tumor treatment
CN113249342B (en) * 2021-05-25 2023-12-01 江苏万戎生物医药科技有限公司 Chimeric broad-spectrum oncolytic adenovirus with multiple mechanism synergistic and synergistic immunotherapy and application thereof in tumor treatment
WO2024015876A1 (en) 2022-07-13 2024-01-18 Epicentrx, Inc. Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100896483B1 (en) * 2007-07-13 2009-05-08 연세대학교 산학협력단 Anti-Tumor Pharmaceutical Composition Comprising Dendritic Cell and Oncolytic Adenovirus Expressing IL-12 and 4-1BBL
US9073980B2 (en) * 2009-03-02 2015-07-07 The Regents Of The University Of California Tumor selective E1a and E1b mutants
KR20180108886A (en) * 2010-03-23 2018-10-04 인트렉손 코포레이션 Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof
RU2013118723A (en) * 2010-09-24 2014-10-27 Онкос Терапьютикс Ой ONCOLITIC Adenovirus VECTORS CODING MONOCLONAL ANTIBODIES AGAINST CTLA-4
ES2759785T3 (en) * 2012-02-02 2020-05-12 Univ Texas Adenoviruses expressing heterologous oncogenic antigens
WO2014170389A1 (en) * 2013-04-18 2014-10-23 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
CN103614416B (en) * 2013-09-30 2016-09-07 中国人民解放军第二军医大学东方肝胆外科医院 A kind of recombination oncolytic adenovirus of carrier's cell-penetrating peptide p53 and GM-CSF gene and application thereof
PL3198009T3 (en) * 2014-09-24 2022-01-24 Salk Institute For Biological Studies Oncolytic tumor viruses and methods of use
US10232053B2 (en) * 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer

Also Published As

Publication number Publication date
AU2018213417A1 (en) 2019-08-15
EP3574090A4 (en) 2021-01-06
KR20190128634A (en) 2019-11-18
MX2019008921A (en) 2019-11-08
WO2018140973A1 (en) 2018-08-02
BR112019015600A2 (en) 2020-03-17
US20190352616A1 (en) 2019-11-21
CA3052090A1 (en) 2018-08-02
JP2020505049A (en) 2020-02-20
EP3574090A1 (en) 2019-12-04
CN110741080A (en) 2020-01-31
IL268291A (en) 2019-09-26

Similar Documents

Publication Publication Date Title
SG11201906973TA (en) Multiple transgene recombinant adenovirus
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201907848YA (en) Antibodies binding to vista at acidic ph
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201407370QA (en) Humanized il-7 rodents
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201805157TA (en) Targeted disruption of the mhc cell receptor
SG11201807025SA (en) Crispr/cas systems for c-1 fixing bacteria
SG11201407483YA (en) Compositions and methods for modulating smn gene family expression
SG11201804662PA (en) Image projection system
SG11201804375WA (en) Compositions and methods for internalizing enzymes
SG11201407561UA (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
SG11201803958WA (en) Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201810757YA (en) Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201906319XA (en) Compositions and methods for the depletion of cd137+ cells
SG11201908456VA (en) Linker units and molecular constructs comprising same
SG11201909520VA (en) Rna for treatment of autoimmune diseases
SG11201906976YA (en) Tumor selective tata-box and caat-box mutants
SG11201907434RA (en) Compositions and methods for immunooncology
SG11201900238UA (en) Compounds and methods for modulation of smn2
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases